Obermatt
See Similar Stocks →

Flags

Financial distress

Xeris Pharmaceuticals

NSQ:XERS · US98422E1038
PharmaceuticalsSmall

360

70
EV / EBIT13
Price / Owner Earnings18
Owner Earnings Yield51
Dividend Yield1
Price/Sales59
EV / Gross Profit42
Price/Book3
Return on Capital87
Cash Return on Capital85
Return on Equity1
EBIT Margin55
Gross Profitability98
Cash Conversion86
Accruals78
Owner Earnings Margin53
Sales growth73
Profit Growth73
Long-Term EPS Growth89
Reinvestment85
Price momentum61
Debt load13
Refinancing74
Debt Payback23
Liquidity63
Analyst ratings55
Opinion Changes50
Price Target Upside62
Market mood73
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Xeris Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2005
Websitexerispharma.com
ISINUS98422E1038
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsChronic DiseasesNeurologyVaccinesEndocrinologyDiabetesCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Xeris Biopharma Holdings, Inc. (‘Xeris’ or ‘Xeris Biopharma’), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. The co…

Analysis

Quality compounder

Xeris Biopharma Holdings, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 51.5×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 19% a year, against analyst forecasts of 26%. The price, in other words, assumes less than the experts do.

Growth is solid; the safety picture is stretched. The company scores 20/20 on our value-creation score: strong value creator.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
81
2023202420252026

All-time high

81

Jun 2026

All-time low

25

Jan 2024

Average rank

47

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
59
43
67
56
Price/Earnings
14
24
24
24
Price/Book
3
97
1
100
Dividend Yield
1
1
1
1
Value (overall)
8
63
21
75

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Xeris Pharmaceuticals with its peers
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →